Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparative study of triamcinolone versus bevacizumab for macular edema and retinal/chorioretinal neovascularization
2007-003032-37Phase 2Completed
- Sponsor
- IRCCS San Matteo Foundation
- Start
- Jul 2007
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of bevacizumab and triamcinolone in macular edema, neovascular retinopathy (NVR) and Subretinal neovascularization (2 arms), sponsored by IRCCS San Matteo Foundation. Primary endpoint: Retinal (macular) thickness. Started Jul 2007; status: completed.
02
Drugs
bevacizumabtriamcinolone
03
Conditions
macular edemaneovascular retinopathy (NVR)Subretinal neovascularization
Beyond the preview
Go deeper on 2007-003032-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003032-37.